We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Magnetically Guided Bacteria Transport Drug-Loaded Liposomes to Hypoxic Tumors

By LabMedica International staff writers
Posted on 24 Aug 2016
A novel transport system for toxic chemotherapeutic drugs is based on a species of bacteria that can be magnetically guided to a tumor where it releases drug-loaded liposomes into the tumor's hypoxic center.

Investigators at Polytechnique Montréal (Canada) described using Magnetococcus marinus strain MC-1 as the foundation for a novel drug delivery system.

Magnetococcus marinus is a species of Alphaproteobacteria that has the peculiar ability to form a structure called a magnetosome, a membrane encased single-magnetic-domain mineral crystals formed by biomineralization, which allows the cells to orientate along the Earth’s geomagnetic field. More...
In their natural environment, MC-1 cells, each containing a chain of magnetic iron-oxide nanocrystals, tend to swim along local magnetic field lines and towards low oxygen concentrations based on a two-state aerotactic sensing system.

The investigators took advantage of this natural tendency of MC-1 cells by using it to transport liposomes that had been loaded with an anticancer drug. Approximately 70 drug-loaded nanoliposomes were attached to each MC-1 cell, which were guided by a computer-controlled external magnetic field.

In a proof-of-principle study published in the August 15, 2016, online edition of the journal Nature Nanotechnology the bacteria were injected near the tumor in severe combined immunodeficient beige mice and magnetically guided. Results indicated that up to 55% of MC-1 cells penetrated into hypoxic regions of HCT116 colorectal xenografts.

"These legions of nanorobotic agents were actually composed of more than 100 million flagellated bacteria - and therefore self-propelled - and loaded with drugs that moved by taking the most direct path between the drug's injection point and the area of the body to cure," said senior author Dr. Sylvain Martel, professor of medical nanorobotics at Polytechnique Montréal. "The drug's propelling force was enough to travel efficiently and enter deep inside the tumors. This innovative use of nanotransporters will have an impact not only on creating more advanced engineering concepts and original intervention methods, but it also throws the door wide open to the synthesis of new vehicles for therapeutic, imaging and diagnostic agents. Chemotherapy, which is so toxic for the entire human body, could make use of these natural nanorobots to move drugs directly to the targeted area, eliminating the harmful side effects while also boosting its therapeutic effectiveness."

Related Links:
Investigators at Polytechnique Montréal


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Test
Allplex HPV28 Detection
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.